Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM · NASDAQ Global Market
+$3.42 today
Vol 1.46M · Avg 0.81M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $62.1M |
| Short-term Investments | $278.5M |
| Receivables | $34.2M |
| Inventory | $28.7M |
| Other Current | $26.6M |
| Total Current Assets | $430.1M |
| PP&E (Net) | $4.0M |
| Intangible Assets | $5.1M |
| Long-term Investments | $601.0K |
| Other Non-current | $2.5M |
| Total Non-current Assets | $12.2M |
| Total Assets | $442.3M |
Analysis
Selected assets total $442.3M for Latest. The largest visible component is Short-term Investments at $278.5M, about 63.0% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $54.3M -39.1% | $89.1M +48.4% | $60.1M -52.9% | $127.7M +115.5% | $59.2M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $334.6M +44.6% | $231.4M +7.3% | $215.8M +4.9% | $205.6M -12.7% | $235.6M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $26.1M +40.9% | $18.5M +24.5% | $14.9M +138.9% | $6.2M +507.2% | $1.0M | $533.8M | $399.4M | -$1.7B |
| Inventory | $25.8M +37.4% | $18.7M +117.3% | $8.6M +195.6% | $2.9M +2527.9% | $111.0K | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $10.0M +13.2% | $8.8M +31.9% | $6.7M -10.0% | $7.4M +85.7% | $4.0M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $466.9M +24.8% | $374.2M +21.4% | $308.3M -13.0% | $354.2M +14.9% | $308.4M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $4.2M +1.1% | $4.1M +93.6% | $2.1M -37.2% | $3.4M -22.1% | $4.3M | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $5.3M -13.8% | $6.2M -12.2% | $7.0M -10.8% | $7.9M +69.2% | $4.7M | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $522.0K | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $998.0K | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $3.3M -57.8% | $7.8M -49.2% | $15.3M -9.8% | $17.0M +39.9% | $12.1M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $14.3M -21.0% | $18.1M -26.2% | $24.5M -13.3% | $28.2M +33.6% | $21.1M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $481.2M +22.7% | $392.3M +17.9% | $332.7M -13.0% | $382.5M +16.1% | $329.5M | $13.3B | $11.9B | $10.6B |
| Account Payables | $13.9M +13.1% | $12.3M +152.4% | $4.9M +1.8% | $4.8M -16.4% | $5.7M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $7.9M | $0 | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $194.0K -84.9% | $1.3M +0.0% | $1.3M -10.3% | $1.4M -79.5% | $7.0M | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $61.4M +40.9% | $43.6M +705.8% | $5.4M +123.6% | $2.4M +202.4% | $800.0K | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $105.9M -8.3% | $115.5M +109.3% | $55.2M +38.7% | $39.8M -8.3% | $43.4M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $235.2M | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $998.0K | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | -$3.3M -103.1% | $108.3M +0.9% | $107.3M +39.1% | $77.2M | $0 | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $236.2M +110.5% | $112.2M +4.1% | $107.8M +37.5% | $78.4M +3931.4% | $1.9M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $342.1M +50.2% | $227.7M +39.7% | $163.0M +37.9% | $118.2M +160.6% | $45.4M | $14.7B | $3.7B | $9.6B |
| Common Stock | $67.0K +9.8% | $61.0K +3.4% | $59.0K +5.4% | $56.0K +12.0% | $50.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$1.4B -17.0% | -$1.2B -29.1% | -$894.7M -26.0% | -$710.1M -34.2% | -$528.9M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$796.0K -1941.0% | -$39.0K -129.1% | $134.0K +245.7% | -$92.0K -9100.0% | -$1.0K | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $139.1M -15.5% | $164.5M -3.1% | $169.8M -35.8% | $264.3M -7.0% | $284.2M | $9.1B | $7.7B | $3.3B |
| Total Debt | $246.5M +6158.8% | $3.9M +212.5% | $1.3M -35.2% | $1.9M -23.8% | $2.6M | $724.2M | $410.6M | $399.4M |
| Net Debt | $192.2M +325.6% | -$85.2M -44.8% | -$58.8M +53.2% | -$125.7M -121.8% | -$56.7M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$34.50B
Nuvalent, Inc.
NASDAQ:NUVL
$9.08B
Protagonist Therapeutics, Inc.
NASDAQ:PTGX
$7.31B
Arcellx, Inc.
ACLX
$6.73B
Akero Therapeutics, Inc.
AKRO
$4.50B
Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSA
$4.16B
uniQure N.V.
NASDAQ:QURE
$2.98B
Relay Therapeutics, Inc.
NASDAQ:RLAY
$2.83B
Stoke Therapeutics, Inc.
NASDAQ:STOK
$1.94B
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.77B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.53B
Ventyx Biosciences, Inc.
VTYX
$1.00B
MeiraGTx Holdings plc
NASDAQ:MGTX
$1.00B
Cullinan Therapeutics, Inc.
NASDAQ:CGEM
$917.57M
Solid Biosciences Inc.
NASDAQ:SLDB
$599.52M
Arvinas, Inc.
NASDAQ:ARVN
$508.43M
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
$366.34M
Inozyme Pharma, Inc.
INZY
$258.25M
Atrium Therapeutics, Inc.
NASDAQ:RNA
$218.04M
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
$98.62M
Pliant Therapeutics, Inc.
NASDAQ:PLRX
$72.45M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does RYTM have?
Rhythm Pharmaceuticals, Inc. (RYTM) reported $54.30M in cash and equivalents in fiscal 2025.
How much debt does RYTM carry?
Rhythm Pharmaceuticals, Inc. (RYTM) reported $246.47M of total debt, with net debt of $192.17M.
Explore More
Continue the stock analysis
Jump to another research area for this company.